Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -21.30% is 100% below its 1-year average of -10.65%, near the low end of its 1-year range (-21.30%–0.00%).
As of the fiscal period ended Wednesday, December 31, 2025. 100.00% below its 12-month average of -10.65%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -3.38%.
RETURN ON ASSETS (ROA)
-21.30%
RETURN ON ASSETS (ROA) AVG TTM
-10.65%
RETURN ON ASSETS (ROA) AVG 3Y
N/A
RETURN ON ASSETS (ROA) AVG 5Y
N/A
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-100.00%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-24.95%
median of 438 covered companies
CURRENT VS SECTOR MEDIAN
+14.63%
vs the sector median at left
Alamar Biosciences, Inc.
Market Cap
$2.64B
Return on Assets (ROA)
-21.30%
TTM Avg
-10.65%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.64B
Return on Assets (ROA)
-6.16%
TTM Avg
-19.77%
3Y Avg
-17.54%
5Y Avg
-23.06%
Market Cap
$2.69B
Return on Assets (ROA)
-20.31%
TTM Avg
-7.83%
3Y Avg
-2.64%
5Y Avg
-2.82%
Market Cap
$2.69B
Return on Assets (ROA)
13.04%
TTM Avg
11.11%
3Y Avg
0.70%
5Y Avg
-8.32%
Market Cap
$2.51B
Return on Assets (ROA)
-42.79%
TTM Avg
-37.88%
3Y Avg
-40.02%
5Y Avg
-36.63%
Market Cap
$2.43B
Return on Assets (ROA)
-2.55%
TTM Avg
-11.61%
3Y Avg
-25.65%
5Y Avg
-35.91%
Market Cap
$2.87B
Return on Assets (ROA)
1.56%
TTM Avg
-4.54%
3Y Avg
-5.50%
5Y Avg
-3.43%
Market Cap
$2.87B
Return on Assets (ROA)
10.36%
TTM Avg
11.11%
3Y Avg
1.40%
5Y Avg
-7.68%
Market Cap
$2.88B
Return on Assets (ROA)
-52.25%
TTM Avg
-41.76%
3Y Avg
-70.33%
5Y Avg
-55.50%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alamar Biosciences, Inc. (ALMR) | $2.64B | -21.30% | -10.65% | N/A | N/A |
| Beam Therapeutics Inc. (BEAM)vs › | $2.64B | -6.16% | -19.77% | -17.54% | -23.06% |
| Acadia Healthcare Company, Inc. (ACHC)vs › | $2.69B | -20.31% | -7.83% | -2.64% | -2.82% |
| Aveanna Healthcare Holdings Inc. (AVAH)vs › | $2.69B | 13.04% | 11.11% | 0.70% | -8.32% |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.51B | -42.79% | -37.88% | -40.02% | -36.63% |
| Clover Health Investments, Corp. (CLOV)vs › | $2.43B | -2.55% | -11.61% | -25.65% | -35.91% |
| AtriCure, Inc. (ATRC)vs › | $2.87B | 1.56% | -4.54% | -5.50% | -3.43% |
| TransMedics Group, Inc. (TMDX)vs › | $2.87B | 10.36% | 11.11% | 1.40% | -7.68% |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.88B | -52.25% | -41.76% | -70.33% | -55.50% |
| ADMA Biologics, Inc. (ADMA)vs › | $2.34B | 24.69% | 32.00% | 9.13% | -4.32% |
ROA
-21.3%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -21.30% |
| 2024-12-31 | 0.00% |
